Table 1.
Recruitment period by study site.
Table 2.
Quantitative outcomes data collected during pre-EoSG data collection phase.
Table 3.
Adolescent characteristics and treatment history.
Fig 1.
Symptom intensity scores reported by adolescents with XLH during the 4-week pre-EoSG period.
(A) Median intensity score for Worst Fatigue (top panel), Worst Pain (middle panel), and Worst Stiffness (bottom panel); (B) Median total symptom intensity scores calculated as the sum of individual symptom scores. Sample sizes (N) varied by week and are indicated below each timepoint. EoSG, end of skeletal growth; IQR, interquartile range; N, number of patients.
Table 4.
Distribution of patients by change in weekly median symptom scores (0–10 NRS) over the 4-week pre-EoSG period.
Table 5.
Pain location and medication use in the pre-EoSG period.
Fig 2.
Weekly median data from wearable device during the 4-week pre-EoSG period.
Panels show (from top to bottom): total daily steps (count), hourly steps (count), time spent in moderate-to-vigorous physical activity (MVPA, minutes); N reflects the number of adolescents with valid wearable data for each respective week. EoSG, end of skeletal growth; MVPA, moderate-to-vigorous physical activity.
Table 6.
Activity diary.
Table 7.
EQ-5D-Y scores in the pre-EoSG period.